📊 CRGT Key Takeaways
Is Cortigent, Inc. (CRGT) a Good Investment?
Cortigent, Inc. presents an uninvestable profile due to complete absence of financial data across all fundamental metrics. The company shows no revenue generation, no profitability data, and minimal operational activity, indicating either pre-revenue stage, dormant status, or reporting deficiencies that preclude meaningful fundamental analysis.
Cortigent's fundamentals are extremely weak: it is still pre-revenue, losses widened in 2025, and operating cash flow remained negative. The balance sheet is distressed, with only about $0.5 million of cash, negative equity, a large working capital deficit, and SEC-filed going-concern language, making the business heavily dependent on external funding rather than internally generated growth.
Why Buy Cortigent, Inc. Stock? CRGT Key Strengths
- No strengths identified
- Operating cost base is still relatively small in absolute dollars versus many medical device development peers
- Total liabilities declined slightly year over year, indicating limited balance-sheet expansion despite continued losses
- Parent funding has supported operations and partially offset cash burn so far
CRGT Stock Risks: Cortigent, Inc. Investment Risks
- No revenue or financial performance data available
- Unable to assess profitability, liquidity, or solvency metrics
- No insider activity or engagement signals in past 90 days
- Complete absence of operational cash flow data
- Cannot evaluate financial health or operational viability
- No revenue from operations in 2024 or 2025, with commercialization still dependent on future regulatory approval
- Net loss increased to $3.1 million in 2025 from $2.2 million in 2024 and operating cash burn rose to $2.7 million
- Severe liquidity pressure: $467,000 cash, $3.8 million working capital deficit, negative equity, and disclosed substantial doubt about continuing as a going concern
Key Metrics to Watch
- Revenue generation and gross margin establishment
- Balance sheet capitalization and liquidity position
- Operating cash flow sustainability
- Quarterly cash balance and operating cash burn
- Revenue generation or regulatory milestones that materially reduce going-concern risk
Cortigent, Inc. (CRGT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CRGT Profit Margin, ROE & Profitability Analysis
CRGT vs Healthcare Sector: How Cortigent, Inc. Compares
How Cortigent, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cortigent, Inc. Stock Overvalued? CRGT Valuation Analysis 2026
Based on fundamental analysis, Cortigent, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cortigent, Inc. Balance Sheet: CRGT Debt, Cash & Liquidity
CRGT Revenue Growth, EPS Growth & YoY Performance
CRGT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cortigent, Inc. (CIK: 0001958489)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRGT
What is the AI rating for CRGT?
Cortigent, Inc. (CRGT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRGT's key strengths?
Claude: . ChatGPT: Operating cost base is still relatively small in absolute dollars versus many medical device development peers. Total liabilities declined slightly year over year, indicating limited balance-sheet expansion despite continued losses.
What are the risks of investing in CRGT?
Claude: No revenue or financial performance data available. Unable to assess profitability, liquidity, or solvency metrics. ChatGPT: No revenue from operations in 2024 or 2025, with commercialization still dependent on future regulatory approval. Net loss increased to $3.1 million in 2025 from $2.2 million in 2024 and operating cash burn rose to $2.7 million.
What is CRGT's revenue and growth?
Cortigent, Inc. reported revenue of N/A.
Does CRGT pay dividends?
Cortigent, Inc. does not currently pay dividends.
Where can I find CRGT SEC filings?
Official SEC filings for Cortigent, Inc. (CIK: 0001958489) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRGT's EPS?
Cortigent, Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CRGT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cortigent, Inc. has a SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CRGT stock overvalued or undervalued?
Valuation metrics for CRGT: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CRGT stock in 2026?
Our dual AI analysis gives Cortigent, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CRGT's free cash flow?
Cortigent, Inc.'s operating cash flow is N/A, with capital expenditures of N/A.
How does CRGT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).